About Actelion

Passion for discovery • Dedication to innovation • Focus on Patients

Over 10 years ago, Drs. Martine and Jean-Paul Clozel, along with their friend and colleague Walter Fischli, made an exciting discovery: a drug that might help those with pulmonary arterial hypertension (PAH).

Their employer at the time, a major pharmaceutical company, decided to abandon the project. Still, the researchers were determined. They firmly believed in the potential of the medicine. And so they risked everything—laying career and personal finances on the line—to start a new company and bring this promising product to market. Actelion and the first oral medication for PAH, Tracleer^® (bosentan), were born.

"There is something magical about discovering and developing a compound that can change someone's life," said Dr. Jean-Paul Clozel, Actelion's CEO. "It's not about faceless diseases—there are people who suffer terribly because of these diseases. At Actelion, we want to make a difference."

Eight years later, Tracleer has made a difference in the lives of over 75,000 patients around the world.¹ And Actelion has firmly cemented its role as a leading innovator in the PAH community.

Driven by innovation

Actelion's commitment to patients with PAH began in the 1980s, when Dr. Martine Clozel and her colleagues were the first scientists to discover an important substance in blood vessels (later named “endothelin”). They believed that blocking this substance was likely to help patients with PAH. Their passion, commitment, and dedication laid the groundwork for the discovery of Tracleer.

Since then, Actelion has continued to pave the way in the treatment of PAH by targeting additional therapeutic pathways.

Leaders now and in the future

As part of Actelion's leadership team, Drs. Martine and Jean-Paul Clozel are still committed to science and the well-being of PAH patients. Innovation remains the driving force behind Actelion's dedication and commitment to the PAH community:

	Extensive ongoing research in PAH1
	Expanding the PAH knowledge base with REVEAL and QuERI patient registries
	Services and support every step of the way with PAH Pathways®

To learn more, visit www.ActelionUS.com.

IMPORTANT SAFETY INFORMATION
Because of the risks associated with Tracleer, this medication may be prescribed by your doctor only through the Tracleer Access Program.

Liver damage: Tracleer can cause serious liver damage, including in rare cases liver failure and, in situations with regular liver testing, unexplained liver cirrhosis. So you must have a blood test to check your liver function before you start Tracleer and each month after that. Call your doctor right away if you have any of these symptoms of liver problems: nausea, vomiting, fever, unusual tiredness, abdominal (stomach area) pain, or yellowing of the skin or the whites of your eyes (jaundice).

Serious birth defects: Tracleer is very likely to cause serious birth defects. It is important not to be or to become pregnant while taking Tracleer or one month after stopping treatment and to have a pregnancy test before you start the drug and each month thereafter. It is very important for you to use reliable forms of birth control while taking Tracleer. Hormonal contraceptives should not be used alone because they may not be effective in patients taking Tracleer.

Do not take Tracleer with glyburide because it may increase your chance of liver injury. Do not take Tracleer with cyclosporine-A because it may increase your chance of side effects.

Please see Additional Safety Information.
Please see full Prescribing Information, including BOXED WARNING and Medication Guide.

1. Data on file, Actelion Pharmaceuticals.